AMS BioteQ Shines at Tokyo Pharma Expo, Targeting Global Market for New Drug Collaborations

AMS BioteQ participated in the prestigious INTERPHEX WEEK TOKYO 2025, held from July 9 to 11, 2025, in Tokyo, Japan.

AMS BioteQ Co., Ltd. (6864-TW) made a grand appearance at the annual pharmaceutical industry event, INTERPHEX WEEK TOKYO 2025, held in Tokyo, Japan, from July 9 to 11, 2025. At this exhibition, AMS BioteQ systematically showcased its core drug development platform technologies and diversified product lines for the first time, focusing on global licensing and cross-border strategic collaborations. This successfully attracted significant attention from numerous multinational pharmaceutical companies, academic research institutions, and potential investment partners.

AMS BioteQ is committed to the innovative development of natural small-molecule drugs, utilizing its self-developed high-efficiency screening technology and AI structure optimization strategies to address unmet clinical needs. At the exhibition, the company introduced its flagship technology platform, ExtrO, which focuses on the efficient purification and controlled release of natural small-molecule components. This significantly enhances the bioavailability and targeted penetration of active ingredients, overcoming the stability and scalability limitations of traditional extraction methods.

AMS BioteQ introduced the AMS-2140 series, an antiviral candidate drug with preclinical development potential, successfully garnering attention.

In terms of R&D products, AMS BioteQ launched the AMS-2140 series, an antiviral candidate drug with preclinical development potential. This series is derived from specific plant extracts and has shown excellent in vitro inhibitory activity against Dengue virus (DENV) and Zika virus (ZIKV). The core lead compound, AMS-2140C, has completed safety evaluations and animal testing. The company plans to collaborate with international pharmaceutical companies and tropical medicine projects through strategic licensing to promote the global market expansion of the new drug.

AMS BioteQ showcased YUAN-01, a highly promising natural anticancer drug.

Additionally, the company showcased YUAN-01, a highly promising natural anticancer drug that exhibits broad-spectrum inhibitory activity against various highly malignant tumors, such as gallbladder cancer, pancreatic cancer, breast cancer, liver cancer, and non-small cell lung cancer. YUAN-01 incorporates liposome embedding technology to enhance drug stability and absorption. According to preliminary research data, YUAN-01 has an IC50 below 10μM in multiple cancer cell lines, with low toxicity to normal cells, indicating its potential for precise therapy. The company has also initiated technology licensing and co-development models, seeking partners in Europe and America to advance clinical trials.

Mr. Tsai Yi Ju, Chairman of AMS BioteQ, stated, "We are committed to using innovative technology to address unmet clinical needs. Through platform licensing and strategic alliances, we aim to develop new drug products with commercialization potential and promote global market expansion." He further noted that the company will accelerate the clinical translation and market implementation of R&D achievements through a dual-track model of "platform technology + innovative drug product lines."

During the exhibition, the company engaged in in-depth discussions with multiple international pharmaceutical companies and academic research institutions.

During the exhibition, AMS BioteQ engaged in in-depth discussions with multiple international pharmaceutical companies and academic research institutions, including specific collaborations on platform technology transfer, API co-development, and joint applications for regional clinical funding. A renowned century-old Japanese pharmaceutical company, the University of Tokyo research team, and international non-profit organizations all expressed strong interest in AMS BioteQ's small-molecule new drugs and proposed specific collaboration plans. Additionally, several well-known pharmaceutical companies inquired about the company's investment strategy and future development direction, indicating the market's growing interest in the small-molecule new drug field.

The successful participation in INTERPHEX WEEK TOKYO 2025 not only highlights AMS BioteQ's leadership in the field of natural innovative drugs but also strengthens its brand image and international influence. In the future, the company will actively deepen its global licensing strategy, focusing on technology licensing and co-development models while leveraging international capital market resources to accelerate the translation of scientific research into market value.

AMS BioteQ stated, "We will continue to invest in innovative R&D and international expansion to fulfill our corporate mission of 'improving human health through technological innovation.' Looking ahead, the company will collaborate with global partners to advance more high-potential drugs into clinical trials and market applications, not only providing patients with more treatment options but also enhancing the international competitiveness of Taiwan's biotechnology industry."